$369.15
+6.64 (+1.83%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ONC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
52 interventional · 1 observational
Held by 14 tracked-famous managers (PRIMECAP MANAGEMENT CO/CA/, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Man Group plc, TWO SIGMA INVESTMENTS, LP, +9 more) · FINRA short interest 2.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 39 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)NCT06073821Cohort 1: Progression Free Survival (PFS）Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Sonrotoclax, Zanubrutinib, Venetoclax, Obinutuzumab | CLL | 652 | Feb 2032 | ≤ 2,020 d | 2026-08-07 |
| A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesNCT07554521Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Tislelizumab, Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin, Leucovorin | Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma | 30 | 2031-12-31 | in 1,960 d | 2026-07-22 |
| A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaNCT07277231Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax | Chronic Lymphocytic Leukemia | 500 | Feb 2031 | ≤ 1,654 d | 2026-08-19 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNCT07770698Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Not yet recruiting | Drug: sonrotoclax, Azacitidine, Inotuzumab ozogamicin, Dexamethasone | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer, Pediatric ALL, Relapsed, Pediatric ALL, Pediatric ALL, B Cell, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric AML, R/R AML, R/R B-cell ALL | 30 | 2030-04-30 | in 1,350 d | 2026-08-18 |
| A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.NCT06697184Number of Participants who Experience Tumor Lysis Syndrome (TLS)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Sonrotoclax, Zanubrutinib | Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL | 258 | 2029-11-30 | in 1,199 d | 2026-08-10 |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsNCT06970743Progression-Free Survival (PFS) by IRCRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: BGB-16673, Bendamustine, Rituximab, Methylprednisolone, Chlorambucil, Obinutuzumab | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 153 | 2029-11-30 | in 1,199 d | 2026-08-10 |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)NCT06943872Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) for Arm A versus Arm DRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Sonrotoclax, Obinutuzumab, Rituximab, Venetoclax | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 630 | 2029-09-30 | in 1,138 d | 2026-08-10 |
| An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid TumorsNCT07222267Part 1: Number of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor | Breast Cancer, Advanced Solid Tumor | 86 | 2029-09-30 | in 1,138 d | 2026-08-14 |
| A First-in-Human Study of BG-C0979 in Adults With Advanced Solid TumorsNCT07414836Phase 1a: Number of Participants Experiencing Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BG-C0979, Tislelizumab | Advanced Solid Tumor | 84 | 2029-04-30 | in 985 d | 2026-08-06 |
| BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641Progression-Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib | HR+/HER2- Breast Cancer | 1,056 | Apr 2029 | ≤ 985 d | 2026-08-19 |
| A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesNCT06634589Substudy 1 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BGB-16673, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab | B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma | 80 | 2028-12-02 | in 836 d | 2026-08-19 |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent | Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer | 399 | Nov 2028 | ≤ 834 d | 2026-08-19 |
| A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsNCT07226349Phase 1a: Number of Participants with Adverse Events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BG-75098, BGB-43395, Fulvestrant | Advanced Solid Tumor | 105 | 2028-11-01 | in 805 d | 2026-08-19 |
| Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid TumorsNCT06598800Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Drug: BG-T187, Other Therapeutic Agents | Advanced Solid Tumor | 153 | 2028-09-30 | in 773 d | 2026-08-07 |
| An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid MalignanciesNCT07619287Part 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BG-75202, Hypomethylation Agent (HMA) | Myeloid Malignancy | 118 | 2028-09-30 | in 773 d | 2026-08-18 |
| A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) MutationsNCT07746141Phase 1a (Part A and Part B): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: BG-85738, Tislelizumab, Cetuximab | RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor | 100 | 2028-09-30 | in 773 d | 2026-08-04 |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)NCT06742996Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC)Randomized · Double-masked · Treatment | Phase 3 | Recruiting | Drug: Sonrotoclax, Zanubrutinib, Placebo | Mantle Cell Lymphoma, B Cell Lymphoma | 300 | 2028-08-31 | in 743 d | 2026-08-19 |
| A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin DiseasesNCT07412691Part A (SAD) and Part B (MAD): Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Biological: BG-A3004, Placebo | Skin Diseases | 98 | 2028-08-08 | in 720 d | 2026-08-10 |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaNCT05100862Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab | Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma | 799 | Jul 2028 | ≤ 712 d | 2026-08-19 |
| A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsNCT06427941Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BGB-B2033, Tislelizumab, Bevacizumab | Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer | 392 | 2028-05-30 | in 650 d | 2026-07-29 |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsNCT06846671Progression-Free Survival (PFS) by Independent Review Committee (IRC)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: BGB-16673, Bendamustine, Idelalisib, Rituximab, Venetoclax | CLL, Chronic Lymphocytic Leukemia | 250 | 2028-05-15 | in 635 d | 2026-08-07 |
| A Study of BGB-B455 in Adults With Advanced or Metastatic Solid TumorsNCT06803680Phase 1a: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BGB-B455, Chemotherapy | Advanced Solid Tumor, Metastatic Solid Tumor | 90 | 2028-04-29 | in 619 d | 2026-08-10 |
| A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT06973187Progression-Free Survival (PFS) per Independent Review Committee (IRC)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: BGB-16673, Pirtobrutinib | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 500 | 2028-04-17 | in 607 d | 2026-08-06 |
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCCNCT07733180Serum Concentrations of Tislelizumab at Specified Time PointsRandomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: Tislelizumab, Oxaliplatin, Leucovorin, 5-fluorouracil (5-FU) | Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | 30 | 2028-02-28 | in 558 d | 2026-07-29 |
| A Study of BGB-11417 in Participants With Myeloid MalignanciesNCT04771130Part 1 And 2: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BGB-11417, Azacitidine, Posaconazole, BGB-11417, BGB-11417 | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm | 260 | 2028-02-08 | in 538 d | 2026-07-13 |
| A Study of BG-C477 in Participants With Advanced Solid TumorsNCT06596473Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BG-C477, Tislelizumab, Chemotherapy | Advanced Solid Tumors | 310 | 2027-12-31 | in 499 d | 2026-08-03 |
| A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)NCT07652736observationalTime from Diagnosis to First Dose | — | Recruiting | Drug: Tislelizumab | Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | 440 | 2027-11-15 | in 453 d | 2026-06-25 |
| A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid TumorsNCT07181681Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BG-C0902 | Solid Tumors, Advanced Solid Tumor | 63 | 2027-11-01 | in 439 d | 2026-05-26 |
| A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous NephropathyNCT05707377Part 1: Change from Baseline in Urine Protein Creatinine Ratio (UPCR)Randomized · Open-label · Treatment | Phase 2/3 | Active, not recruiting | Drug: Zanubrutinib, Tacrolimus | Primary Membranous Nephropathy | 178 | Oct 2027 | ≤ 438 d | 2026-07-23 |
| A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT07043400Model-Predicted Steady State Trough Concentration (Ctrough) of TislelizumabRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin, Leucovorin, 5-fluorouracil (5-FU), Oxaliplatin, Capecitabine | Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 351 | 2027-10-30 | in 437 d | 2026-08-07 |
| A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid TumorsNCT05981703Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BGB-26808, Tislelizumab, Chemotherapy | Advanced Solid Tumor, Solid Tumor | 217 | 2027-09-30 | in 407 d | 2026-06-03 |
| An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid TumorsNCT06589596Phase 1a: Number of Participants with Adverse Events and Serious Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BGB-58067, BG-89894, Standard of Care Therapy | Advanced Solid Tumor | 525 | 2027-09-30 | in 407 d | 2026-07-22 |
| Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid TumorsNCT06233942Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BG-C9074, Tislelizumab, Bevacizumab | Advanced Solid Tumor | 308 | 2027-09-28 | in 405 d | 2026-07-08 |
| BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast CancerNCT06756932Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BGB-21447, Fulvestrant, BGB-43395 | Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer | 120 | 2027-07-30 | in 345 d | 2026-06-22 |
| A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy ParticipantsNCT07712640Area under the Plasma Concentration-Time Curve from Time 0 Infinity (AUC0-inf) for BGB-58067Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BGB-58067 Tablet (F-01 Formulation), BGB-58067 Tablet (F-02 Formulation) | Healthy Volunteers | 32 | 2027-07-01 | in 316 d | 2026-08-10 |
| Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell MalignanciesNCT04277637Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: Sonrotoclax, Zanubrutinib, Obinutuzumab | Mature B-Cell Malignancies | 437 | 2027-05-31 | in 285 d | 2026-06-22 |
| A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationNCT04002297Progression-free survival (PFS) determined by independent central reviewRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: zanubrutinib, bendamustine, rituximab | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | 510 | Mar 2027 | ≤ 224 d | 2026-05-18 |
| A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid TumorsNCT06625593Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BG-C137, Anticancer Agents | Advanced Solid Tumor | 168 | 2026-12-31 | in 134 d | 2026-07-09 |
| A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaNCT04973605Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide | Relapsed/Refractory Multiple Myeloma | 246 | Nov 2026 | ≤ 103 d | 2026-08-07 |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesNCT05006716Phase 1: Number of Participants with Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: BGB-16673 | B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma | 645 | Nov 2026 | ≤ 103 d | 2026-08-19 |
| A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaNCT06637501Complete Response (CR)/ Complete Response with Incomplete Bone Marrow Recovery (CRi) RateRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Sonrotoclax, Zanubrutinib | Chronic Lymphocytic Leukemia | 94 | Nov 2026 | ≤ 103 d | 2026-07-09 |
| A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy ParticipantsNCT07590102Part A and Part B: Time of the Maximum Observed Concentration (Tmax) of BGB-58067Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: BGB-58067, Phenytoin, Itraconazole | Healthy Volunteers | 30 | 2026-09-30 | in 42 d | 2026-07-22 |
| A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy AdultsNCT07628881Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) for SonrotoclaxRandomized · Open-label · Other | Phase 1 | Recruiting | Drug: Sonrotoclax Tablet for Oral Suspension, Sonrotoclax Tablet | Healthy Volunteers | 12 | 2026-09-27 | in 39 d | 2026-07-09 |
| A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaNCT05952037Cohort 1: Major Response Rate (MRR)Non-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Sonrotoclax, Zanubrutinib | Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory | 114 | 2026-09-22 | in 34 d | 2026-01-02 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesNCT05828589Part 1: Number of participants with dose limiting toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns. | Drug: BGB-21447 | Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma | 51 | 2026-06-08actual | — | 2026-07-14 |
| Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesNCT04164199Number of Participants with Immune-Mediated Adverse Events, Serious Adverse Events, and Adverse Events Grade 3 or HigherNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Tislelizumab, Pamiparib, Temozolomide, Sitravatinib, Ociperlimab, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007 | Advanced Malignancies | 404 | 2026-05-23actual | — | 2026-06-03 |
| A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid TumorsNCT06422520Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BGB-C354, Tislelizumab | Advanced Solid Tumor | 63 | 2026-05-15actual | — | 2026-06-08 |
| BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT06253195Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BGB-43395, Fulvestrant, Letrozole | Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer | 33 | 2026-04-23actual | — | 2026-06-10 |
| A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationNCT06585488Phase 1a: Number of Participants Experiencing Adverse Events (AEs)Randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape. | Drug: BGB-53038, Tislelizumab, Cetuximab | Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Esophageal Adenocarcinoma | 47 | 2026-04-23actual | — | 2026-07-08 |
| A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerNCT06685718Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Evaluation on business strategy, not involving safety issue. | Drug: BG-60366 | Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), EGFR Activating Mutation, EGFR Mutation-Related Tumors | 33 | 2026-04-21actual | — | 2026-05-22 |
| An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid TumorsNCT06568614Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was discontinued following an internal decision by the sponsor | Drug: BG-89894 | Advanced or Metastatic MTAP-deleted Solid Tumors | 29 | 2026-04-13actual | — | 2026-05-12 |
| A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid TumorsNCT06487858Phase 1a: Number of Participant with Adverse Events, Serious Adverse Events, Adverse Events of Clinical Interest and Dose-limiting ToxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: This decision is due to a company business decision with a strategy change on the BGB-R046 development in Advanced or Metastatic Solid Tumors. | Drug: BGB-R046, Tislelizumab | Solid Tumor | 42 | 2026-04-09actual | — | 2026-05-11 |
| A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy AdultsNCT07141511Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-inf) for zanubrutinibRandomized · Open-label · Other | Phase 1 | Completed | Drug: BG-71332, Zanubrutinib, Sonrotoclax | Healthy Volunteers | 24 | 2026-02-23actual | — | 2026-04-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19